CA2492060A1 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment - Google Patents
Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment Download PDFInfo
- Publication number
- CA2492060A1 CA2492060A1 CA002492060A CA2492060A CA2492060A1 CA 2492060 A1 CA2492060 A1 CA 2492060A1 CA 002492060 A CA002492060 A CA 002492060A CA 2492060 A CA2492060 A CA 2492060A CA 2492060 A1 CA2492060 A1 CA 2492060A1
- Authority
- CA
- Canada
- Prior art keywords
- theta
- compound according
- degrees
- characteristic peaks
- angina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]- 2- propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, a nd methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
Claims (31)
1. A compound which is crystalline carvedilol dihydrogen phosphate hemihydrate.
2. The compound according to claim 1 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta as shown in Figure 1.
3. The compound according to claim 2 having characteristic peaks from 0° degrees 2-theta (2.theta.) to 35° degrees 2-theta (2.theta.) at about 7.0 ~
0.2 (2.theta.), 11.4 ~ 0.2 (2.theta.), 15.9 ~ 0.2 (2.theta.), 18.8 ~ 0.2 (2.theta.), 20.6 ~ 0.2 (2.theta.), 22.8 ~
0.2 (2.theta.), and 25.4 ~ 0.2 (2.theta.).
0.2 (2.theta.), 11.4 ~ 0.2 (2.theta.), 15.9 ~ 0.2 (2.theta.), 18.8 ~ 0.2 (2.theta.), 20.6 ~ 0.2 (2.theta.), 22.8 ~
0.2 (2.theta.), and 25.4 ~ 0.2 (2.theta.).
4. The compound according to claim 1 having an infrared spectrum which comprises characteristic absortion bands expressed in wave numbers as shown in Figure 6.
5. The compound according to claim 1 having a Raman spectrum which comprises characteristic peaks as shown in Figure 3.
6. A compound which is carvedilol dihydrogen phosphate dehydrate.
7. The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2.theta.) as shown in Figure 9.
8. The compound according to claim 7 having characteristic peaks from 0° degrees 2-theta (2.theta.) to 35° degrees 2-theta (2.theta.) at about 6.5 ~
0.2 (2.theta.), 7.1 ~ 0.2 (2.theta.), 13.5 ~ 0.2 (2.theta.), 14.0 ~ 0.2 (2.theta.), 17.8 ~ 0.2 (2.theta.), 18.9 ~
0.2 (2.theta.), and 21.0 ~ 0.2 (2.theta.).
0.2 (2.theta.), 7.1 ~ 0.2 (2.theta.), 13.5 ~ 0.2 (2.theta.), 14.0 ~ 0.2 (2.theta.), 17.8 ~ 0.2 (2.theta.), 18.9 ~
0.2 (2.theta.), and 21.0 ~ 0.2 (2.theta.).
9. The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2.theta.) as shown in Figure 25.
10. The compound according to claim 9 having characteristic peaks from 0° degrees 2-theta (2.theta.) to 35° degrees 2-theta (28) at about 6.4 ~
0.2 (2.theta.), 9.6 ~ 0.2 (2.theta.), 16.0 ~ 0.2 (2.theta.), 18.4 ~ 0.2 (2.theta.), 20.7 ~ 0.2 (2.theta.), and 24.5 ~ 0.2 (2.theta.).
0.2 (2.theta.), 9.6 ~ 0.2 (2.theta.), 16.0 ~ 0.2 (2.theta.), 18.4 ~ 0.2 (2.theta.), 20.7 ~ 0.2 (2.theta.), and 24.5 ~ 0.2 (2.theta.).
11. A compound which is carvedilol dihydrogen phosphate methanol solvate.
12. The compound according to claim 11 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2.theta.) as shown in Figure 24.
13. The compound according to claim 12 having characteristic peaks from 0° degrees 2-theta (2.theta.) to 35° degrees 2-theta (2.theta.) at about 6.9 ~
0.2 (2.theta.), 7.2 ~ 0.2 (2.theta.), 13.5 ~ 0.2 (2.theta.), 14.1 ~ 0.2 (2.theta.), 17.8 ~ 0.2 (2.theta.), and 34.0 ~ 0.2 (2.theta.).
0.2 (2.theta.), 7.2 ~ 0.2 (2.theta.), 13.5 ~ 0.2 (2.theta.), 14.1 ~ 0.2 (2.theta.), 17.8 ~ 0.2 (2.theta.), and 34.0 ~ 0.2 (2.theta.).
14. A compound which is carvedilol dihydrogen phosphate.
15. The compound according to claim 14 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2.theta.) as shown in Figure 28.
16. The compound according to claim 15 having characteristic peaks from 0° degrees 2-theta (2.theta.) to 35° degrees 2-theta (2.theta.) at about 13.2 ~
0.2 (2.theta.), 15.8 ~ 0.2 (2.theta.), 16.3 ~ 0.2 (2.theta.), 21.2 ~ 0.2 (2.theta.), 23.7 ~ 0.2 (2.theta.), and 26.0 ~ 0.2 (2.theta.).
0.2 (2.theta.), 15.8 ~ 0.2 (2.theta.), 16.3 ~ 0.2 (2.theta.), 21.2 ~ 0.2 (2.theta.), 23.7 ~ 0.2 (2.theta.), and 26.0 ~ 0.2 (2.theta.).
17. A compound which is carvedilol hydrogen phosphate.
18. The compound according to claim 17 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (28) as shown in Figure 29.
19. The compound according to claim 18 having characteristic peaks from 0° degrees 2-theta (2.theta.) to 35° degrees 2-theta (2A) at about 5.5 ~
0.2 (2.theta.), 12.3 ~ 0.2 (2.theta.), 15.3 ~ 0.2 (2.theta.), 19.5 ~ 0.2 (2.theta.), 21.6 ~ 0.2 (2.theta.), and 24.9 ~ 0.2 (2.theta.).
0.2 (2.theta.), 12.3 ~ 0.2 (2.theta.), 15.3 ~ 0.2 (2.theta.), 19.5 ~ 0.2 (2.theta.), 21.6 ~ 0.2 (2.theta.), and 24.9 ~ 0.2 (2.theta.).
20. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
21. A pharmaceutical composition comprising the compound according to claim 6 and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising the compound according to claim 14 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising the compound according to claim 17 and a pharmaceutically acceptable carrier.
24. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 1.
25. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 6.
26. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 14.
27. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 17.
28. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 20.
29. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 21.
30. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 22.
31. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 23.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39217502P | 2002-06-27 | 2002-06-27 | |
US60/392,175 | 2002-06-27 | ||
PCT/US2003/020408 WO2004002419A2 (en) | 2002-06-27 | 2003-06-27 | Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2492060A1 true CA2492060A1 (en) | 2004-01-08 |
CA2492060C CA2492060C (en) | 2011-11-01 |
Family
ID=30000823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2492060A Expired - Lifetime CA2492060C (en) | 2002-06-27 | 2003-06-27 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
Country Status (15)
Country | Link |
---|---|
US (6) | US7268156B2 (en) |
EP (1) | EP1534270A4 (en) |
JP (3) | JP2005533823A (en) |
KR (3) | KR20110134952A (en) |
CN (6) | CN101898995B (en) |
AU (1) | AU2003248746B2 (en) |
BR (1) | BR0312102A (en) |
CA (1) | CA2492060C (en) |
EA (1) | EA008384B1 (en) |
IL (1) | IL165814A (en) |
MX (1) | MXPA04012923A (en) |
NO (1) | NO329710B1 (en) |
NZ (1) | NZ537161A (en) |
WO (1) | WO2004002419A2 (en) |
ZA (1) | ZA200410011B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030017569A (en) | 2000-06-28 | 2003-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | Carvedilol |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
JP2005515226A (en) | 2002-01-15 | 2005-05-26 | テバ ファーマシューティカル インダストリーズ リミティド | Crystalline solids of carvedilol and methods for preparing them |
AU2003231283A1 (en) * | 2002-04-30 | 2003-11-17 | Sb Pharmco Puerto Rico Inc. | Carvedilol monocitrate monohydrate |
MXPA04012923A (en) * | 2002-06-27 | 2005-03-31 | Sb Pharmco Inc | Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment. |
AU2003251627A1 (en) | 2002-06-27 | 2004-01-19 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
CN1694959B (en) | 2002-09-13 | 2013-09-18 | 雷普利瑟公司 | Non-sequence complementary antiviral oligonucleotides |
WO2005051383A1 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
EP1691789B1 (en) * | 2003-11-25 | 2017-12-20 | SmithKline Beecham (Cork) Limited | Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
EP1781611A1 (en) * | 2005-06-09 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of carvedilol and processes for their preparation |
WO2007144900A2 (en) * | 2006-06-14 | 2007-12-21 | Matrix Laboratories Limited | Carvedilol phosphate sesquihydrate |
US8022094B2 (en) * | 2006-06-28 | 2011-09-20 | Teva Pharmaceutical Industries Ltd. | Carvedilol phosphate |
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008084494A1 (en) * | 2007-01-08 | 2008-07-17 | Matrix Laboratories Limited | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same |
US20080207726A1 (en) * | 2007-02-26 | 2008-08-28 | Santiago Ini | Process for the purification of carvedilol or its salts thereof |
WO2008104990A1 (en) * | 2007-02-27 | 2008-09-04 | Lupin Limited | Amorphous carvedilol dihydrogen phosphate |
US20080249317A1 (en) * | 2007-04-04 | 2008-10-09 | Apotex Inc. | Novel amorphous form of carvedilol phosphate and processes for the preparation thereof |
WO2008142703A1 (en) * | 2007-05-17 | 2008-11-27 | Wanbury Limited | A novel cost effective process for production of carvedilol phosphate |
EP2014649A1 (en) * | 2007-06-27 | 2009-01-14 | Inke, S.A. | Novel amorphous carvedilol dihydrogen phosphate |
WO2009008009A1 (en) * | 2007-07-11 | 2009-01-15 | Lupin Limited | Novel crystalline form b of carvedilol dihydrogen phosphate |
US20100076047A1 (en) * | 2007-08-20 | 2010-03-25 | Sankar Reddy Budidet | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt |
US8278461B2 (en) | 2007-08-21 | 2012-10-02 | Lupin Limited | Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer |
WO2009035535A2 (en) * | 2007-09-07 | 2009-03-19 | Scinopharm Taiwan Ltd. | Method of crystallizing carvedilol phosphate and the product thereof |
US20090111998A1 (en) * | 2007-10-25 | 2009-04-30 | Srinivas Reddy Gade | Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof |
US20110015247A1 (en) * | 2008-04-04 | 2011-01-20 | Shodhana Laboratories Limited | Novel crystalline form of carvedilol dihydrogen phosphate and related processes |
US7763645B2 (en) * | 2008-05-23 | 2010-07-27 | Wanbury Limited | Carvedilol dihydrogen phosphate monohydrate |
CN101891671B (en) * | 2010-07-26 | 2012-06-27 | 天津大学 | Crystals of carvidilol dihydric phosphate and preparation method thereof |
US8492426B1 (en) * | 2012-07-12 | 2013-07-23 | Anis Ahmad | Use of carvedilol for treatment of diabetes mellitus |
CN106892858A (en) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | A kind of carvidilol dihydric phosphate novel crystal forms |
US10357476B1 (en) | 2018-10-30 | 2019-07-23 | Anis Ahmad | Method for treating coronary artery disease |
CN110279662A (en) * | 2019-06-05 | 2019-09-27 | 合肥合源药业有限公司 | A kind of solid dispersions and preparation method and application of insoluble drug Carvedilol |
US10772869B1 (en) | 2019-07-24 | 2020-09-15 | ECI Pharmaceuticals, LLC | Pharmaceutical compositions including carvedilol and methods of using the same |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (en) | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US4053067A (en) * | 1973-06-25 | 1977-10-11 | Westinghouse Electric Corporation | Fuel transfer system for a nuclear reactor |
DE3319027A1 (en) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBAZOL DERIVATIVES, NEW R- AND S-CARBAZOL DERIVATIVES, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US4985464A (en) | 1984-05-23 | 1991-01-15 | Rudolf Happle | Drug compositions for local treatment of alopecia areata |
US5405863A (en) * | 1992-12-01 | 1995-04-11 | Smithkline Beecham Corporation | Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
US5308862A (en) * | 1993-03-05 | 1994-05-03 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation |
US5393772A (en) * | 1993-11-24 | 1995-02-28 | Boehringer Mannheim Pharmaceuticals Corporation | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation |
US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
US20010011099A1 (en) | 1995-05-30 | 2001-08-02 | Smithkline Beecham Corporation | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
EP0910374A1 (en) | 1996-07-13 | 1999-04-28 | Roche Diagnostics GmbH | Pharmaceutical formulations for topical application containing as an active ingredient a carbazolyl-(4)-oxy-propanol amine derivate |
US6096777A (en) * | 1996-08-23 | 2000-08-01 | Boehringer Mannheim Pharmaceuticals Corporation | Method for inhibiting the expression of Fas |
JP2002512591A (en) * | 1996-10-09 | 2002-04-23 | ベーリンガー・マンハイム・ファーマシューティカルズ・コーポレイション―スミスクライン・ビーチャム・コーポレイション・リミテッド・パートナーシップ・ナンバー1 | Inhibition of stress-activated protein kinases |
EP0893440A1 (en) | 1997-07-22 | 1999-01-27 | Roche Diagnostics GmbH | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
US6730326B2 (en) * | 1997-07-22 | 2004-05-04 | Roche Diagnostics Gmbh | Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it |
GT199800126A (en) * | 1997-08-29 | 2000-01-29 | COMBINATION THERAPY. | |
ZA989365B (en) * | 1997-10-15 | 1999-04-15 | Boehringer Mannheim Pharm Corp | Preparation for treating alzheimer's disease |
US20020054911A1 (en) | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
US6852337B2 (en) * | 1998-04-09 | 2005-02-08 | Roche Diagnostics Gmbh | Carvedilol-galenics |
DE69910188T2 (en) | 1998-04-09 | 2004-06-17 | Roche Diagnostics Gmbh | MEDICINE CONTAINING CARVEDILOL |
DE19833119A1 (en) | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Storage-stable injectable solution of vasodilator and beta blocker Carvedilol contains buffer, organic solvent, antioxidant and complexing agent |
US6664284B2 (en) * | 1998-07-23 | 2003-12-16 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
PE20001302A1 (en) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE |
US6515010B1 (en) * | 1999-11-15 | 2003-02-04 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
US20020068740A1 (en) * | 1999-12-07 | 2002-06-06 | Mylari Banavara L. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
EP1272180B1 (en) * | 2000-04-03 | 2004-09-29 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
AU5066101A (en) * | 2000-04-13 | 2001-10-30 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
DK174645B1 (en) * | 2000-05-18 | 2003-08-04 | Gea Farmaceutisk Fabrik As | Process and intermediates for the preparation of 1- (9H-carbazol-4-yloxy) -3- [2- (2-methoxy-phenoxy) -ethylamino] -propan-2-ol, carvedilol and acid addition salts thereof |
KR20030017569A (en) * | 2000-06-28 | 2003-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | Carvedilol |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
EP1385509A4 (en) | 2001-04-02 | 2004-06-30 | Smithkline Beecham Corp | Method of treatment |
IN191028B (en) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
FI20011464A0 (en) | 2001-07-04 | 2001-07-04 | Orion Corp | Combination therapy for the treatment of heart failure |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US20050019399A1 (en) | 2001-09-21 | 2005-01-27 | Gina Fischer | Controlled release solid dispersions |
CA2460486A1 (en) | 2001-09-28 | 2003-04-10 | F. Hoffmann-La Roche Ag | Pseudopolymorphic forms of carvedilol |
WO2003028645A2 (en) | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel compositions of carvedilol |
WO2003028718A1 (en) | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
JP2005504815A (en) | 2001-10-02 | 2005-02-17 | スミスクライン・ビーチャム・コーポレイション | New composition of carvedilol |
US20040019096A1 (en) | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
JP2005515226A (en) * | 2002-01-15 | 2005-05-26 | テバ ファーマシューティカル インダストリーズ リミティド | Crystalline solids of carvedilol and methods for preparing them |
AU2003231283A1 (en) | 2002-04-30 | 2003-11-17 | Sb Pharmco Puerto Rico Inc. | Carvedilol monocitrate monohydrate |
MXPA04012923A (en) * | 2002-06-27 | 2005-03-31 | Sb Pharmco Inc | Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment. |
US20040152756A1 (en) | 2002-07-15 | 2004-08-05 | Wei Chen | Carvedilol polymorph |
KR20040010306A (en) | 2002-07-22 | 2004-01-31 | (주)나노하이브리드 | A Hybrid Of Itraconazole, Cyclosporine Or Carvedilol With A Layered Silicate And A Process For Preparing The Same |
ES2204303B2 (en) * | 2002-08-07 | 2004-12-16 | Laboratorios Vita, S.A. | PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND. |
WO2004016249A1 (en) | 2002-08-14 | 2004-02-26 | Ranbaxy Laboratories Limited | Extended release matrix tablets |
US20040151772A1 (en) | 2002-11-08 | 2004-08-05 | Egalet A/S | Controlled release carvedilol compositions |
AU2003288608A1 (en) | 2002-12-20 | 2004-07-14 | Ranbaxy Laboratories Limited | Controlled release, multiple unit drug delivery systems |
WO2005051383A1 (en) | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
EP1691789B1 (en) | 2003-11-25 | 2017-12-20 | SmithKline Beecham (Cork) Limited | Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
EP1686967A4 (en) | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
-
2003
- 2003-06-27 MX MXPA04012923A patent/MXPA04012923A/en active IP Right Grant
- 2003-06-27 AU AU2003248746A patent/AU2003248746B2/en not_active Expired
- 2003-06-27 CN CN201010152481XA patent/CN101898995B/en not_active Expired - Lifetime
- 2003-06-27 NZ NZ537161A patent/NZ537161A/en not_active IP Right Cessation
- 2003-06-27 WO PCT/US2003/020408 patent/WO2004002419A2/en active Application Filing
- 2003-06-27 EP EP03762176A patent/EP1534270A4/en not_active Ceased
- 2003-06-27 KR KR1020117028711A patent/KR20110134952A/en not_active Application Discontinuation
- 2003-06-27 CN CN2013100986020A patent/CN103288715A/en active Pending
- 2003-06-27 CN CN2013100984468A patent/CN103333099A/en active Pending
- 2003-06-27 CN CN2013100984947A patent/CN103288714A/en active Pending
- 2003-06-27 US US10/518,654 patent/US7268156B2/en not_active Expired - Lifetime
- 2003-06-27 KR KR1020137033808A patent/KR20140006111A/en not_active Application Discontinuation
- 2003-06-27 CA CA2492060A patent/CA2492060C/en not_active Expired - Lifetime
- 2003-06-27 CN CN2013100984294A patent/CN103254114A/en active Pending
- 2003-06-27 JP JP2004518025A patent/JP2005533823A/en not_active Withdrawn
- 2003-06-27 BR BRPI0312102-0A patent/BR0312102A/en not_active Application Discontinuation
- 2003-06-27 KR KR1020137008295A patent/KR101468827B1/en active IP Right Grant
- 2003-06-27 CN CNA038202301A patent/CN1678305A/en active Pending
- 2003-06-27 EA EA200500091A patent/EA008384B1/en not_active IP Right Cessation
-
2004
- 2004-12-10 ZA ZA200410011A patent/ZA200410011B/en unknown
- 2004-12-16 IL IL165814A patent/IL165814A/en not_active IP Right Cessation
-
2005
- 2005-01-25 NO NO20050427A patent/NO329710B1/en not_active IP Right Cessation
-
2007
- 2007-06-25 US US11/767,581 patent/US7759384B2/en not_active Expired - Lifetime
- 2007-06-25 US US11/767,566 patent/US20070259940A1/en not_active Abandoned
- 2007-06-25 US US11/767,573 patent/US7626041B2/en not_active Expired - Lifetime
- 2007-06-25 US US11/767,586 patent/US7902378B2/en not_active Expired - Lifetime
- 2007-06-25 US US11/767,578 patent/US7893100B2/en active Active
-
2010
- 2010-12-17 JP JP2010282048A patent/JP5422545B2/en not_active Expired - Lifetime
-
2013
- 2013-08-02 JP JP2013161656A patent/JP2013241450A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2492060A1 (en) | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | |
RS20060097A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
BG63630B1 (en) | Crystalline hemicalcium salt of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methyletyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h- pyrol-1-heptane acid (atorvastatin) | |
RS20050915A (en) | Substituted indazolyl(indolyl) maleimide derivatives as kinase inhibitors | |
CY2461B1 (en) | Polymorphic compounds. | |
BR0212277A (en) | Compound, process for preparing a compound, use of a compound, method for producing an ibat inhibitory effect, and pharmaceutical composition | |
RS20050180A (en) | Novel benzoimidazole derivatives useful as antiproliferative agensts | |
MXPA05003093A (en) | Diaryl ethers as opioid receptor antagonist. | |
CA2356300A1 (en) | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | |
RO116900B1 (en) | Dihydrobenzopyran derivatives, process for preparing the same, intermediate for carrying-out the process, pharmaceutical compound and method of treatment | |
BR0212345A (en) | Compound, process for preparing a compound, use of a compound, method for producing an inhibitory effect of ileal bile acid in a warm-blooded animal and pharmaceutical composition | |
TNSN03083A1 (en) | Mercaptoacetylamide derivatives, a process for their preparation and their use | |
WO2001017963A3 (en) | Aminoalkoxy carbazoles and their use as 5-ht ligands | |
WO2004104001A3 (en) | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase | |
AU7660594A (en) | Method for the preparation of high purity substituted benz {e}indoles and the alkaline salts thereof | |
CA2335514A1 (en) | Alkyl ether analogs of chlorins having an n-substituted imide ring | |
IL133225A0 (en) | (+)-Norcisapride useful for 5-ht3 and 5ht4 mediated disorders | |
RS20050890A (en) | Substituted pyrrole derivatives | |
AU5705099A (en) | Compounds useful as aicarft inhibitors | |
WO2004002472A8 (en) | Carvedilol hydrobromide | |
AU2003242896A1 (en) | Solvent-free process for the preparation of diketopyrrolopyrrole derivatives | |
GR3031282T3 (en) | New n-benzoylmethyl substituted paroxetine derivatives | |
AU2002339158A1 (en) | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | |
IL162058A0 (en) | Hexacyclic compounds | |
JP2008500327A (en) | Salt form of atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20230627 |